161 related articles for article (PubMed ID: 27481579)
1. Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis.
Bogani G; Fucà G; Maltese G; Ditto A; Martinelli F; Signorelli M; Chiappa V; Scaffa C; Sabatucci I; Lecce F; Raspagliesi F; Lorusso D
Gynecol Oncol; 2016 Nov; 143(2):443-447. PubMed ID: 27481579
[TBL] [Abstract][Full Text] [Related]
2. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
Ricci S; Giuntoli RL; Eisenhauer E; Lopez MA; Krill L; Tanner EJ; Gehrig PA; Havrilesky LJ; Secord AA; Levinson K; Frasure H; Celano P; Fader AN
Gynecol Oncol; 2013 Dec; 131(3):629-33. PubMed ID: 24016408
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
[TBL] [Abstract][Full Text] [Related]
4. Role of bevacizumab in uterine leiomyosarcoma.
Bogani G; Ditto A; Martinelli F; Signorelli M; Chiappa V; Fonatella C; Sanfilippo R; Leone Roberti Maggiore U; Ferrero S; Lorusso D; Raspagliesi F
Crit Rev Oncol Hematol; 2018 Jun; 126():45-51. PubMed ID: 29759566
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
Littell RD; Tucker LY; Raine-Bennett T; Palen TE; Zaritsky E; Neugebauer R; Embry-Schubert J; Lentz SE
Gynecol Oncol; 2017 Oct; 147(1):11-17. PubMed ID: 28747255
[TBL] [Abstract][Full Text] [Related]
6. Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.
Chae SH; Shim SH; Chang M; Choi AY; Kang GG; Lee SJ; Kim SN
Gynecol Oncol; 2019 Sep; 154(3):638-650. PubMed ID: 31307664
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma.
Wu TI; Chang TC; Hsueh S; Hsu KH; Chou HH; Huang HJ; Lai CH
Gynecol Oncol; 2006 Jan; 100(1):166-72. PubMed ID: 16182349
[TBL] [Abstract][Full Text] [Related]
8. Uterine leiomyosarcoma--a Singapore experience.
Soh LT; Chew SH; Ang L
Aust N Z J Obstet Gynaecol; 1999 May; 39(2):246-8. PubMed ID: 10755790
[TBL] [Abstract][Full Text] [Related]
9. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities.
Vaz J; Tian C; Richardson MT; Chan JK; Mysona D; Rao UN; Powell MA; Shriver CD; Hamilton CA; Casablanca Y; Maxwell GL; Darcy KM
Gynecol Oncol; 2020 Apr; 157(1):121-130. PubMed ID: 31954536
[TBL] [Abstract][Full Text] [Related]
10. Impact of perioperative characteristics on the recurrence risk and survival of patients with uterine leiomyosarcoma.
Gracia M; Yildirim Y; Macuks R; Mancari R; Achimas-Cadariu P; Cusine-Lopez L; Novak Z; Dallaku K; Zapardiel I;
Int J Gynaecol Obstet; 2023 Dec; 163(3):868-874. PubMed ID: 37485666
[TBL] [Abstract][Full Text] [Related]
11. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
Seagle BL; Sobecki-Rausch J; Strohl AE; Shilpi A; Grace A; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):61-70. PubMed ID: 28317559
[TBL] [Abstract][Full Text] [Related]
12. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
Friedman CF; Hensley ML
Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the efficacy and trends of adjuvant therapy versus observation in women with early stage (uterine confined) leiomyosarcoma: a National Cancer Database study.
Costales AB; Radeva M; Ricci S
J Gynecol Oncol; 2020 May; 31(3):e21. PubMed ID: 32266798
[TBL] [Abstract][Full Text] [Related]
14. The treatment of uterine leiomyosarcoma: clinical outcomes of 18 cases and the effectiveness of chemotherapy.
Matoda M; Takeshima N; Nomura H; Kino M; Omatsu K; Iwase H; Umayahara K; Takizawa K
Eur J Gynaecol Oncol; 2011; 32(6):647-50. PubMed ID: 22335027
[TBL] [Abstract][Full Text] [Related]
15. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
Gupta AA; Yao X; Verma S; Mackay H; Hopkins L;
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):346-55. PubMed ID: 23295078
[TBL] [Abstract][Full Text] [Related]
16. Trends in the treatment of uterine leiomyosarcoma in the Medicare population.
Foley OW; Rauh-Hain JA; Clemmer J; Clark RM; Hall T; Diver EJ; Schorge JO; del Carmen MG
Int J Gynecol Cancer; 2015 Mar; 25(3):453-8. PubMed ID: 25628107
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant treatment for uterine leiomyosarcoma.
Akers SN; Groman A; Odunsi K; Lele S; Frederick PJ
Eur J Gynaecol Oncol; 2013; 34(5):409-14. PubMed ID: 24475573
[TBL] [Abstract][Full Text] [Related]
18. Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis.
Rizzo A; Nannini M; Astolfi A; Indio V; De Iaco P; Perrone AM; De Leo A; Incorvaia L; Di Scioscio V; Pantaleo MA
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32674439
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.
Omura GA; Blessing JA; Major F; Lifshitz S; Ehrlich CE; Mangan C; Beecham J; Park R; Silverberg S
J Clin Oncol; 1985 Sep; 3(9):1240-5. PubMed ID: 3897471
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the efficacy of systemic therapy for advanced uterine leiomyosarcoma: A systematic review, meta-analysis, and meta-regression analysis.
Ijaz I; Shahzad MN; Hosseinifard H; Liu S; Sefidan MO; Kahloon LE; Imani S; Hua Z; Zhang YQ
Cancer Med; 2023 Jul; 12(13):13894-13911. PubMed ID: 37081717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
